| 6.09 Data as of May 17 |  -0.01 / -0.16%Today’s Change | 3.00 Today|||52-Week Range 8.25 | +17.12% Year-to-Date |
| Wider-Than-Expected Loss at Anacor - Analyst Blog May 13 / Zacks.com |
| Previous close | 6.10 |
| Today’s open | 6.11 |
| Day’s range | 5.98 - 6.19 |
| Volume | 930,678 |
| Average volume (3 months) | 641,416 |
| Market cap | $246.6M |
| Dividend yield | -- |
| Earnings growth (last year) | -2.92% |
| Earnings growth (this year) | +9.52% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -47.11% |
| P/E ratio | NM |
| Price/Sales | 15.45 |
| Price/Book | 45.05 |
| Today’s change | Today’s % change | |
|---|---|---|
| ACRXAcelRx Pharmaceutica... | -0.51 | -7.09% |
| CRTXCornerstone Therapeu... | +0.09 | +1.01% |
| RGLSRegulus Therapeutics... | -0.14 | -1.93% |
| INSYInsys Therapeutics I... | -0.04 | -0.36% |
| Next reporting date | August 15, 2013 |
| EPS forecast (this quarter) | -$0.39 |
| Annual revenue (last year) | $10.7M |
| Annual profit (last year) | -$56.1M |
| Net profit margin | -522.23% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director David P. Perry, MBA |
Chief Financial Officer & Senior Vice President Geoffrey M. Parker, MBA |
Corporate headquarters Palo Alto, California |
.
